Comparison between Single-Dose and Two-Dose Psilocybin Administration in the Treatment of Major Depression: A Systematic Review and Meta-Analysis of Current Clinical Trials
Brain Sciences August 18, 2024 Gianmarco Salvetti, Daniele Saccenti, Andrea Stefano Moro et al. 16 citations
Psilocybin, a psychedelic compound, shows high effectiveness in reducing depressive symptoms in people with major depressive disorder (MDD) or treatment-resistant depression (TRD). A systematic review and meta-analysis of 12 studies found that both single-dose and two-dose psilocybin treatments significantly lowered depression severity. Two-dose administration sometimes produced more pronounced and lasting effects, but it remains unclear whether this is due to dosage or other factors. The findings suggest psilocybin is a promising emerging treatment for these conditions, though standardized trials comparing dosing strategies are needed.